scholarly journals Extracorporeal Partial Nephrectomy with Orthotopic Autotransplantation under Pharmaco-Cold Ischaemia for Cancer of a Single Kidney: A Case Report

2020 ◽  
Vol 13 (3) ◽  
pp. 1202-1208
Author(s):  
Tatiana Baitman ◽  
Irina Miroshkina ◽  
Alexander Gritskevich ◽  
Alexander Teplov ◽  
Andrey Zotikov ◽  
...  
Keyword(s):  
Inferior Vena ◽  
Advanced Disease ◽  
Locally Advanced ◽  
Vena Cava ◽  
Distant Metastases ◽  
Cancer Specific Survival ◽  
Nephron Sparing ◽  
Radical Method ◽  
Single Kidney

Up to 10% of patients with renal cell carcinoma (RCC) have locally advanced disease with venous tumour thrombosis involving the inferior vena cava (IVC). 30–50% of them present with synchronous metastatic disease. Surgical treatment remains the only potentially radical method for patients suffering from RCC and IVC tumour thrombosis without distant metastases. Five-year cancer-specific survival for such patients is 40–60%. The role of surgery in the treatment of RCC is significant, even if only cytoreductive operation is possible. Nephron-sparing surgery (NSS) is reasonably preferable for patients suffering from single kidney RCC, but it is not always radical enough. Extracorporeal approach allows to perform a radical dissection of the tumour in special complicated cases, but it is seldom used because of technical difficulties. We present a case of successful NSS by extracorporeal approach in our modification for RCC with IVC tumour thrombosis.

scholarly journals Management of Locally Advanced Renal Cell Carcinoma with Invasion of the Duodenum

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Andrew T. Schlussel ◽  
Aaron B. Fowler ◽  
Herbert K. Chinn ◽  
Linda L. Wong
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Inferior Vena ◽  
Locally Advanced ◽  
Vena Cava ◽  
En Bloc Resection ◽  
Bloc Resection ◽  
En Bloc

Renal cell carcinoma (RCC) is rare but aggressive, with greater than 20% of patients presenting with stage III or IV, disease. Surgical resection of the primary tumor regardless of stage is the treatment of choice, and en bloc resection of involved organs provides the only potential chance for cure. This case report describes a patient with metastatic right-sided RCC with invasion of the inferior vena cava and duodenum managed by en block resection and pancreaticoduodenectomy. This report will review the workup and treatment of locally advanced RCC, as well as the role of cytoreductive nephrectomy in the setting of metastatic disease.

scholarly journals Role of Inferior Vena Cava Filter Retrieval in Patients on Chronic Anticoagulation Therapy

2021 ◽  
Vol 23 (2) ◽  
Author(s):  
Savannah Fletcher ◽  
Adam Plotnik ◽  
Ravi N. Srinivasa ◽  
Jeffrey Forris Beecham Chick ◽  
John M. Moriarty
Keyword(s):  
Inferior Vena Cava ◽  
Inferior Vena Cava Filter ◽  
Inferior Vena ◽  
Treatment Options ◽  
Anticoagulation Therapy ◽  
Vena Cava ◽  
Vena Cava Filter ◽  
Venous Thromboembolic

Abstract Purpose of review Describe the role of inferior vena cava filter (IVCF) retrieval in patients on chronic anticoagulation given the overlap of these treatment options in the management of patients with venous thromboembolic disease. Recent findings Despite the increase in IVCF retrievals since the Food and Drug Administration safety communications in 2010 and 2014, retrieval rates remain low. Previous studies have shown that longer filter dwell times are associated with greater risk for filter complications and more difficulty with filter retrievals. Recent findings suggest that complications are more frequent in the first 30 days after placement. Summary The decision to retrieve an optional IVCF is individualized and requires diligent follow-up with consistent re-evaluation of the need for the indwelling IVCF, particularly in those on long-term anticoagulation therapy.

Role of right heart receptors in the control of renin, vasopressin, and cortisol secretion in dogs

1992 ◽  
Vol 263 (5) ◽  
pp. R1071-R1077 ◽  
Author(s):  
D. H. Carr ◽  
D. B. Jennings ◽  
T. N. Thrasher ◽  
L. C. Keil ◽  
D. J. Ramsay
Keyword(s):  
Inferior Vena ◽  
Vena Cava ◽  
Plasma Renin ◽  
Atrial Pressure ◽  
Right Atrial ◽  
Right Heart ◽  
Hormonal Responses ◽  
The Right ◽  
Maximal Reduction

We have reported that increased left heart pressure inhibits increases in plasma renin activity (PRA), arginine vasopressin (AVP), and cortisol during arterial hypotension. The goal of this study was to determine whether increases in right heart pressure also inhibited hormonal responses to hypotension. Seven dogs were chronically instrumented with inflatable cuffs around the ascending aorta (AA), the pulmonary artery (PA), and the thoracic inferior vena cava (IVC), as well as with catheters in both atria, the abdominal aorta, and vena cava. The IVC, the PA, and the AA cuffs were inflated on different days to cause step reductions in mean arterial pressure (MAP) of 5, 10, 20, and 30% below control MAP. Graded constriction of the AA caused large increases in left atrial pressure and plasma atrial natriuretic peptide (ANP), but had no effect on plasma AVP or cortisol and caused only a small increase in PRA at the maximal reduction of MAP. Constriction of the IVC reduced both atrial pressures and plasma ANP, but stimulated increases in PRA, AVP, and cortisol. Constriction of the PA increased right atrial pressure and plasma ANP and caused increases in plasma AVP and cortisol that were similar to responses during IVC constriction, but the PRA response was only half (P < 0.05). These results indicate that increasing pressure on the right side of the heart can attenuate the PRA response to hypotension, and suggest that the inhibition is mediated by the rise in plasma ANP.

scholarly journals Role of Lung Ultrasound and Inferior Vena Cava Diameter in Assessment of Patients with Heart Failure

2021 ◽  
Vol 85 (2) ◽  
pp. 4102-4107
Author(s):  
Hussein Abd El-Fattah Mohammed ◽  
Mohamed Salah El-Feshawy ◽  
Fareed Shawky Basiony ◽  
Mustafa Abu shady
Keyword(s):  
Heart Failure ◽  
Inferior Vena Cava ◽  
Inferior Vena ◽  
Lung Ultrasound ◽  
Vena Cava ◽  
Patients With Heart Failure ◽  
Inferior Vena Cava Diameter

scholarly journals Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4939
Author(s):  
Alberto Servetto ◽  
Antonio Santaniello ◽  
Fabiana Napolitano ◽  
Francesca Foschini ◽  
Roberta Marciano ◽  
...  
Keyword(s):  
Median Overall Survival ◽  
Locally Advanced ◽  
Distant Metastases ◽  
Ductal Adenocarcinoma ◽  
Controlled Clinical Trials ◽  
Single Institution ◽  
Locally Advanced Pancreatic Adenocarcinoma ◽  
Grade 3 ◽  
Advanced Pancreatic Adenocarcinoma

Patients with locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) do not present distant metastases but are not eligible for surgery upfront. Chemotherapy regimens, such as FOLFIRINOX (FFN) or nab-paclitaxel plus gemcitabine (GemNab) in combination with loco-regional treatments are generally used in this setting. However, the best treatment choice is unknown. We retrospectively analyzed the information of 225 patients with stage II–III PDAC treated at our institution between October 2011 and December 2020. A total of 94 patients with LA PDAC who are non-eligible for surgery upfront received neoadjuvant FFN or GemNab. Of the 67 patients receiving FFN, 28 (41.8%) underwent surgery after neoadjuvant therapy. Of the 27 patients treated with GemNab, 6 (22.2%) became eligible for resection. The median overall survival (OS) was 85.1 weeks and 54.3 weeks in the FFN and GemNab groups, respectively (HR = 0.54, p = 0.0109). The median OS was 189.7 weeks and 76.4 weeks in the resected and unresected cohorts, respectively (HR = 0.25, p < 0.0001). Neutropenia (37.3%), anemia (6.0%), and diarrhea (6.0%) in the FFN group and neutropenia (22.2%) and thrombocytopenia (18.5%) in the GemNab groups were the most frequent grade 3–4 side effects. Higher rates of thrombocytosis (p < 0.0001) and peripheral edema (p < 0.0001) were observed in the GemNab group. Our results suggest that the use of FFN is associated with more favorable clinical outcomes than GemNab for patients with LA PDAC. Future randomized and controlled clinical trials are needed to further elucidate the role of these regimens and loco-regional treatments in this setting.

scholarly journals Role of presurgical targeted molecular therapy in renal cell carcinoma with an inferior vena cava tumor thrombus

2018 ◽  
Vol Volume 11 ◽  
pp. 1997-2005 ◽  
Author(s):  
Cheng Peng ◽  
Liangyou Gu ◽  
Lei Wang ◽  
Qingbo Huang ◽  
Baojun Wang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Inferior Vena Cava ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Inferior Vena ◽  
Vena Cava ◽  
Molecular Therapy ◽  
Targeted Molecular Therapy

Role of inferior vena cava ultrasound in diagnosis of shock in patients with trauma

2020 ◽  
Vol 39 (1) ◽  
pp. 194
Author(s):  
ZaynabM El Sayed ◽  
KhalidY.A Youssif ◽  
MohammedA Ali ◽  
AmrM Moghazy
Keyword(s):  
Inferior Vena Cava ◽  
Inferior Vena ◽  
Vena Cava
Sign in / Sign up

Export Citation Format

Share Document